Telemonitoring for chronic obstructive pulmonary disease: a cost and cost-utility analysis of a randomised controlled trial

Andrew Stoddart*, Marjon van der Pol, Hilary Pinnock, Janet Hanley, Lucy McCloughan, Allison Todd, Ashma Krishan, Brian McKinstry

*Corresponding author for this work

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We compared the costs and cost-effectiveness of telemonitoring vs usual care for patients with chronic obstructive pulmonary disease (COPD). A total of 256 patients were randomised to either telemonitoring or usual care. In the telemonitoring arm, the touch-screen telemonitoring equipment transmitted data to clinical teams monitoring the patients. Total healthcare costs were estimated over a 12-month period from a National Health Service perspective and quality adjusted life year (QALYs) were estimated by the EQ-5D tool. Telemonitoring was not significantly more costly than usual care (mean difference per patient £2065.90 (P < 0.18). The increased costs were predominantly due to telemonitoring service costs and non-significantly higher secondary care costs. Telemonitoring for COPD was not cost-effective at a base case of £137,277 per QALY with only 15% probability of being cost-effective at the usual threshold of £30,000 per QALY. Although there was some statistical and methodological uncertainty in the measures used, telemonitoring was not cost-effective in the sensitivity analyses performed. It seems unlikely that a telemonitoring service of the kind that was trialled would be cost-effective in providing care for people with COPD.

Original languageEnglish
Pages (from-to)108-118
Number of pages11
JournalJournal of telemedicine and telecare
Volume21
Issue number2
Early online date13 Jan 2015
DOIs
Publication statusPublished - 1 Mar 2015

Keywords

  • whole systems demonstrator
  • global burden
  • telehealth
  • care
  • exacerbation
  • mortality
  • program
  • COPD

Cite this

Telemonitoring for chronic obstructive pulmonary disease : a cost and cost-utility analysis of a randomised controlled trial. / Stoddart, Andrew; van der Pol, Marjon; Pinnock, Hilary; Hanley, Janet; McCloughan, Lucy; Todd, Allison; Krishan, Ashma; McKinstry, Brian.

In: Journal of telemedicine and telecare, Vol. 21, No. 2, 01.03.2015, p. 108-118.

Research output: Contribution to journalArticle

Stoddart, Andrew ; van der Pol, Marjon ; Pinnock, Hilary ; Hanley, Janet ; McCloughan, Lucy ; Todd, Allison ; Krishan, Ashma ; McKinstry, Brian. / Telemonitoring for chronic obstructive pulmonary disease : a cost and cost-utility analysis of a randomised controlled trial. In: Journal of telemedicine and telecare. 2015 ; Vol. 21, No. 2. pp. 108-118.
@article{e6271d862f05453881ed65b61a97bb71,
title = "Telemonitoring for chronic obstructive pulmonary disease: a cost and cost-utility analysis of a randomised controlled trial",
abstract = "We compared the costs and cost-effectiveness of telemonitoring vs usual care for patients with chronic obstructive pulmonary disease (COPD). A total of 256 patients were randomised to either telemonitoring or usual care. In the telemonitoring arm, the touch-screen telemonitoring equipment transmitted data to clinical teams monitoring the patients. Total healthcare costs were estimated over a 12-month period from a National Health Service perspective and quality adjusted life year (QALYs) were estimated by the EQ-5D tool. Telemonitoring was not significantly more costly than usual care (mean difference per patient £2065.90 (P < 0.18). The increased costs were predominantly due to telemonitoring service costs and non-significantly higher secondary care costs. Telemonitoring for COPD was not cost-effective at a base case of £137,277 per QALY with only 15{\%} probability of being cost-effective at the usual threshold of £30,000 per QALY. Although there was some statistical and methodological uncertainty in the measures used, telemonitoring was not cost-effective in the sensitivity analyses performed. It seems unlikely that a telemonitoring service of the kind that was trialled would be cost-effective in providing care for people with COPD.",
keywords = "whole systems demonstrator, global burden, telehealth, care, exacerbation, mortality, program , COPD",
author = "Andrew Stoddart and {van der Pol}, Marjon and Hilary Pinnock and Janet Hanley and Lucy McCloughan and Allison Todd and Ashma Krishan and Brian McKinstry",
year = "2015",
month = "3",
day = "1",
doi = "10.1177/1357633X14566574",
language = "English",
volume = "21",
pages = "108--118",
journal = "Journal of telemedicine and telecare",
issn = "1357-633X",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Telemonitoring for chronic obstructive pulmonary disease

T2 - a cost and cost-utility analysis of a randomised controlled trial

AU - Stoddart, Andrew

AU - van der Pol, Marjon

AU - Pinnock, Hilary

AU - Hanley, Janet

AU - McCloughan, Lucy

AU - Todd, Allison

AU - Krishan, Ashma

AU - McKinstry, Brian

PY - 2015/3/1

Y1 - 2015/3/1

N2 - We compared the costs and cost-effectiveness of telemonitoring vs usual care for patients with chronic obstructive pulmonary disease (COPD). A total of 256 patients were randomised to either telemonitoring or usual care. In the telemonitoring arm, the touch-screen telemonitoring equipment transmitted data to clinical teams monitoring the patients. Total healthcare costs were estimated over a 12-month period from a National Health Service perspective and quality adjusted life year (QALYs) were estimated by the EQ-5D tool. Telemonitoring was not significantly more costly than usual care (mean difference per patient £2065.90 (P < 0.18). The increased costs were predominantly due to telemonitoring service costs and non-significantly higher secondary care costs. Telemonitoring for COPD was not cost-effective at a base case of £137,277 per QALY with only 15% probability of being cost-effective at the usual threshold of £30,000 per QALY. Although there was some statistical and methodological uncertainty in the measures used, telemonitoring was not cost-effective in the sensitivity analyses performed. It seems unlikely that a telemonitoring service of the kind that was trialled would be cost-effective in providing care for people with COPD.

AB - We compared the costs and cost-effectiveness of telemonitoring vs usual care for patients with chronic obstructive pulmonary disease (COPD). A total of 256 patients were randomised to either telemonitoring or usual care. In the telemonitoring arm, the touch-screen telemonitoring equipment transmitted data to clinical teams monitoring the patients. Total healthcare costs were estimated over a 12-month period from a National Health Service perspective and quality adjusted life year (QALYs) were estimated by the EQ-5D tool. Telemonitoring was not significantly more costly than usual care (mean difference per patient £2065.90 (P < 0.18). The increased costs were predominantly due to telemonitoring service costs and non-significantly higher secondary care costs. Telemonitoring for COPD was not cost-effective at a base case of £137,277 per QALY with only 15% probability of being cost-effective at the usual threshold of £30,000 per QALY. Although there was some statistical and methodological uncertainty in the measures used, telemonitoring was not cost-effective in the sensitivity analyses performed. It seems unlikely that a telemonitoring service of the kind that was trialled would be cost-effective in providing care for people with COPD.

KW - whole systems demonstrator

KW - global burden

KW - telehealth

KW - care

KW - exacerbation

KW - mortality

KW - program

KW - COPD

U2 - 10.1177/1357633X14566574

DO - 10.1177/1357633X14566574

M3 - Article

VL - 21

SP - 108

EP - 118

JO - Journal of telemedicine and telecare

JF - Journal of telemedicine and telecare

SN - 1357-633X

IS - 2

ER -